$60,000 of IMMUNITYBIO INC. lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"None"
You can find more data on corporate lobbying on Quiver Quantitative.
IBRX Insider Trading Activity
IBRX insiders have traded $IBRX stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $IBRX stock by insiders over the last 6 months:
- BARRY J. SIMON has made 0 purchases and 5 sales selling 401,967 shares for an estimated $3,778,685.
- CHRISTOBEL SELECKY has made 0 purchases and 3 sales selling 100,000 shares for an estimated $687,650.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
IBRX Hedge Fund Activity
We have seen 156 institutional investors add shares of IBRX stock to their portfolio, and 89 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HEIGHTS CAPITAL MANAGEMENT, INC removed 6,565,709 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $13,000,103
- BLACKROCK, INC. added 5,790,256 shares (+29.2%) to their portfolio in Q4 2025, for an estimated $11,464,706
- STATE STREET CORP added 5,139,890 shares (+45.4%) to their portfolio in Q4 2025, for an estimated $10,176,982
- VANGUARD GROUP INC added 5,122,052 shares (+18.5%) to their portfolio in Q4 2025, for an estimated $10,141,662
- CITIGROUP INC removed 2,271,488 shares (-95.4%) from their portfolio in Q4 2025, for an estimated $4,497,546
- TWO SIGMA INVESTMENTS, LP added 2,109,983 shares (+80.9%) to their portfolio in Q4 2025, for an estimated $4,177,766
- WOODLINE PARTNERS LP removed 1,851,185 shares (-34.9%) from their portfolio in Q4 2025, for an estimated $3,665,346
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
IBRX Analyst Ratings
Wall Street analysts have issued reports on $IBRX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 02/23/2026
- Piper Sandler issued a "Overweight" rating on 01/20/2026
- D. Boral Capital issued a "Buy" rating on 01/20/2026
To track analyst ratings and price targets for IBRX, check out Quiver Quantitative's $IBRX forecast page.
IBRX Price Targets
Multiple analysts have issued price targets for $IBRX recently. We have seen 7 analysts offer price targets for $IBRX in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $23.0 on 04/08/2026
- Jeet Mukherjee from BTIG set a target price of $13.0 on 03/12/2026
- Edward Tenthoff from Piper Sandler set a target price of $12.0 on 03/04/2026
- Andres Y. Maldonado from HC Wainwright & Co. set a target price of $15.0 on 02/23/2026
- Kelly Shi from Jefferies set a target price of $9.0 on 12/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
